載入中
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
前收盤價
US$7.82
US$0.00 · 0.00%
盤中時間採用ET。市場資料可能有所延遲。
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
日內區間
目前US$7.82
52週區間
目前US$7.82
盤中時間採用ET。市場資料可能有所延遲。
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
日內區間
目前US$7.82
52週區間
目前US$7.82
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1.58億 USD | 1.25億 USD | 8614萬 USD | 8227.4萬 USD | 5110萬 USD |
| 銷售、一般及管理費用 | 2100.1萬 USD | 1774.1萬 USD | 1882.1萬 USD | 2471.4萬 USD | 2039.1萬 USD |
| 營業費用 | 1.79億 USD | 1.42億 USD | 1.05億 USD | 1.07億 USD | 7149.1萬 USD |
| 利息收入 | 1622.4萬 USD | 1268.2萬 USD | 832.5萬 USD | 222.8萬 USD | 44.2萬 USD |
| 折舊和攤銷 | 49萬 USD | 39.3萬 USD | 37.7萬 USD | 35.7萬 USD | 16.3萬 USD |
| 營業利益 | −1.79億 USD | −1.42億 USD | −1.05億 USD | −1.07億 USD | −7149.1萬 USD |
| 淨利 | −1.62億 USD | −1.29億 USD | −9665.5萬 USD | −1.05億 USD | −7109.6萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$28.33
上漲空間 262.28%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2723.58萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1700.15萬0.17%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1614.54萬0.02%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF687.92萬0.01%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO469.92萬0.03%180億 USD0.06%US$112.66+0.50%
Dimensional - US Small Cap ETFDFAS446.39萬0.01%338.69億 USD0.31%US$78.35+0.32%
iShares Biotechnology ETFIBB425.84萬0.04%108.2億 USD0.44%US$206.49+3.00%
Fidelity Enhanced Small Cap ETFFESM369.04萬0.06%64.1億 USD0.28%US$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
